In a report released on May 15, Andrew Berens from SVB Securities maintained a Hold rating on Elevation Oncology (ELEV – Research Report), with a price target of $5.00. The company’s shares closed yesterday at $3.80.
According to TipRanks, Berens is a 3-star analyst with an average return of 1.9% and a 48.48% success rate. Berens covers the Healthcare sector, focusing on stocks such as AstraZeneca, Incyte, and Zentalis Pharmaceuticals.
Currently, the analyst consensus on Elevation Oncology is a Moderate Buy with an average price target of $4.50.
See Insiders’ Hot Stocks on TipRanks >>
ELEV market cap is currently $86.86M and has a P/E ratio of -0.90.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition.
Read More on ELEV:
